The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342
Open accessAbstract
Purpose: Cancer and Leukemia Group B Protocol 9342 was initiated to determine the optimal dose of paclitaxel administered as a 3-hour infusion every 3 weeks to women with metastatic breast cancer. Patients and Methods: Four hundred seventy-four women with metastatic breast cancer who had received one or no prior chemotherapy regimens were randomly assigned to one of three paclitaxel dosing regimens—175 mg/m 2, 210 mg/m 2, or 250 mg/m 2—each administered as a 3-hour infusion every 3 weeks. Women completed self-administered quality of life and symptom assessment questionnaires at baseline and after three cycles of treatment. Results: No evidence of a significant dose-response relationship was demonstrated over the dose range assessed. Response rates were 23%, 26%, and 21% for the three regimens, respectively. A marginally significant association (P = .04) was seen between dose and time to progression; however, in a multivariate analysis, the difference was even less apparent. No statistically significant difference was seen in survival. Neurotoxicity and hematologic toxicity were more severe on the higher dose arms. There was no significant difference in quality of life on the three arms. Conclusion: Higher doses of paclitaxel administered as a 3-hour infusion to women with metastatic breast cancer did not improve response rate, survival, or quality of life. There was a slight improvement in time to progression with higher dose therapy, which was offset by greater toxicity. When a 3-hour infusion of paclitaxel is administered every 3 weeks, 175 mg/m 2 should be considered the optimal dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Group Psychosocial Support on Survival in Metastatic Breast Cancer
Goodwin, P. J., Leszcz, M., Ennis, M., Koopmans, J., Vincent, L., Guther, H., Drysdale, E., Hundleby, M., Chochinov, H. M., Navarro, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011871 · Cited by 891
THE IMPACT OF NATIONAL CANCER ACT
(1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797 · Cited by 796
Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
Holmes, F. A., Walters, R. S., Theriault, R. L., Buzdar, A. U., Frye, D. K., Hortobagyi, G. N., Forman, A. D., Newton, L. K., & Raber, M. N. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797-a · Cited by 746
Bonomi, P., Kim, K., Fairclough, D., Cella, D., Kugler, J., Rowinsky, E., Jiroutek, M., & Johnson, D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.623 · Cited by 589
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
Wood, W. C., Budman, D. R., Korzun, A. H., Cooper, M. R., Younger, J., Hart, R. D., Moore, A., Ellerton, J. A., Norton, L., Ferree, C. R., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301801 · Cited by 577
Self-citationDose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
(1994) · New England Journal of Medicine · doi:10.1056/nejm199407143310226 · Cited by 556
Stadtmauer, E. A., O'Neill, A., Goldstein, L. J., Crilley, P. A., Mangan, K. F., Ingle, J. N., Brodsky, I., Martino, S., Lazarus, H. M., Erban, J. K., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004133421501 · Cited by 460
Nabholtz, J. M., Gelmon, K., Bontenbal, M., Spielmann, M., Catimel, G., Conte, P., Klaassen, U., Namer, M., Bonneterre, J., Fumoleau, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1858 · Cited by 380
Seidman, A. D., Hudis, C. A., Albanell, J., Albanel, J., Tong, W., Tepler, I., Currie, V, Moynahan, M. E., Theodoulou, M., Gollub, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3353 · Cited by 378
Self-citationCoates, A., Gebski, V, Signorini, D., Murray, P., McNeil, D., Byrne, M., & Forbes, J. F. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.12.1833 · Cited by 313
Fisher, B., Anderson, S., Wickerham, D. L., DeCillis, A., Dimitrov, N., Mamounas, E., Wolmark, N., Pugh, R., Atkins, J. N., Meyers, F. J., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1858 · Cited by 308
Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines
Lopes, N. M., Adams, E. G., Pitts, T. W., & Bhuyan, B. K. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685842 · Cited by 271
Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer
Perez, E. A., Vogel, C. L., Irwin, D. H., Kirshner, J. J., & Patel, R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4216 · Cited by 250
Self-citationReichman, B. S., Seidman, A. D., Crown, J. P., Heelan, R., Hakes, T. B., Lebwohl, D. E., Gilewski, T. A., Surbone, A., Currie, V, & Hudis, C. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1943 · Cited by 237
Self-citationFisher, B., Anderson, S., DeCillis, A., Dimitrov, N., Atkins, J. N., Fehrenbacher, L., Henry, P. H., Romond, E. H., Lanier, K. S., Davila, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3374 · Cited by 225
Herndon, J. E., Fleishman, S., Kornblith, A. B., Kosty, M., Green, M. R., & Holland, J. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990115)85:2<333::aid-cncr10>3.0.co;2-q · Cited by 193
Self-citationQuality-of-Life Scores Predict Outcome in Metastatic but Not Early Breast Cancer
Coates, A. S., Hürny, C., Peterson, H. F., Bernhard, J., Castiglione-Gertsch, M., Gelber, R. D., Goldhirsch, A., & for the International Breast Cancer Study Group (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3768 · Cited by 181
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
Baselga, J. M., Seidman, A. D., Rosen, P. P., & Norton, L. (1997) · PubMed · Cited by 157
Self-citationSmith, R. E., Brown, A. M., Mamounas, E. P., Anderson, S., Lembersky, B. C., Atkins, J. H., Shibata, H. R., Báez, L., DeFusco, P. A., Davila, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3403 · Cited by 151
Llobera, J., Esteva, M., Rifà, J., Benito, E., Terrasa, J., Rojas, C., Pons, O., Catalán, G., & Avella Mestre, A. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00291-4 · Cited by 150
Quality-of-life assessment: performance status upstaged?
Weeks, J. L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.12.1827 · Cited by 52
(1998) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(19980701)83:1 · Cited by 3
Cited by
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Multistage nanoparticle delivery system for deep penetration into tumor tissue
Wong, C., Stylianopoulos, T., Cui, J., Martin, J., Chauhan, V. P., Jiang, W., Popović, Z., Jain, R. K., Bawendi, M. G., & Fukumura, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018382108 · Cited by 1,062
Yeh, M.-K., Chang, H.-I., & Cheng, M.-Y. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s26766 · Cited by 801
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Protein nanoparticles as drug carriers in clinical medicine
Hawkins, M. J., Soon-Shiong, P., & Desai, N. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.044 · Cited by 779
Metadata
- Authors
- Winer, E. P., Berry, D. A., Woolf, S., Duggan, D., Kornblith, A., Harris, L. N., Michaelson, R. A., Kirshner, J. A., Fleming, G. F., Perry, M. C., Graham, M. L., Sharp, S. A., Keresztes, R., Henderson, I. C., Hudis, C., Muss, H., & Norton, L.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-06-01
- Volume
- 22
- Issue
- 11
- Pages
- 2061-2068
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2143989581
- Cited by
- 270
- References
- 22
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.